PRELIMINARY PROGRAMME Masterclass in molecular oncology 29-31 January 2015 - Prague, Czech Republic Dear delegate, A warm welcome to all attending the “Masterclass in molecular oncology”. I would like to inform you that as of 28 April 2014 the name of our Foundation changed to EXCEMED – Excellence in Medical Education. The name change will not impact your registration status in this or any other Foundation event. This transition marks an exciting point in the evolution of the Foundation. We are proud to have provided world-class education to thousands of healthcare professionals over the past four decades - as a result, the Foundation has become synonymous with delivery excellence and highimpact CME. As we further develop our scientific and geographical presence it is important to us that our name accurately reflects the independent nature of the education we provide; EXCEMED symbolises our enduring mission to support the best possible outcomes for patients through the medical education we offer. We take pride in our complete dedication to the provision of CME - it is our sole focus and our passion. I wish you an inspiring and successful learning experience here in Prague. Yours sincerely, Rachel Clark CEO, EXCEMED 1 Aim Precision medicine in oncology is an evolving landscape. In recent years new insights have been gained into driver genomic alterations responsible for cancer progression. The identification of a growing number of molecular targets and the availability of specific targeted therapies are fueling the clinical research and rapidly changing clinical practice. The aim of this masterclass in molecular oncology is to describe the basic principles of cancer genomics, techniques in molecular biology and translational research. This live educational intensive course will provide insights into the new taxonomy of cancer, the molecular pathways relevant for therapy and the methodology in molecular diagnosis of cancer. Educational Format This highly interactive course is designed to deliver effective knowledge in molecular oncology. The aim is to make the expertise of recognized key opinion leaders available to the learners, providing them with the opportunity to clarify doubts and solve uncertainties in the field of molecular oncology. For this purpose, the educational format will be based on a series of lessons, followed by direct interactions among experts and learners, during the curricular activities in the meeting rooms and outside. Learning objectives After attending this masterclass in molecular oncology learners will be able to: • Define relevant molecular pathways in oncology • Distinguish genome analysis methods • Illustrate personalized treatment options for cancer patients Target audience Medical oncologists who want to improve their knowledge in molecular biology platforms for targeted therapy and drug discovery. 2 Accreditation An application will be made to the EACCME® for CME accreditation of this EXCEMED live educational course “Masterclass in molecular oncology” to be held on 29-31 January 2015 in Prague, Czech Republic. An application has been made to the ESMO for CME accreditation. EXCEMED adheres to the principles of the Good CME Practice Group (gCMEp). Register to EXCEMED website: www.oncology.excemed.org follow us on EXCEMED_Onco http://twitter.com/EXCEMED_Onco 3 Chairmen and coordinators of the steering committee Eric Van Cutsem University Hospitals Gasthuisberg / Leuven Leuven, Belgium Yosef Yarden Weizmann Institute of Science Department of Biological Regulation Rehovot, Israel Share your opinion with us We are always looking for ways to bring our educational activities to the next level and meet your needs as a healthcare practitioner. You will be asked to answer a post-event online survey to find out if the experience met your educational expectations. Your views also help us tailor future initiatives. Thank you for taking the time to participate. Scientific secretariat EXCEMED - Excellence in Medical Education Salita di San Nicola da Tolentino, 1/b 00187 Rome, Italy Programme Manager: Giovanna Rossi T +39 06 420 413 252 - F +39 06 420 413 677 E-mail: email@example.com Specialist Medical Advisor: Cristina Raimondi EXCEMED is a Swiss Foundation with headquarters in 14, Rue du Rhône, 1204 Geneva, Switzerland Organising secretariat Meridiano Congress International Via Sapri, 6 - 00185 Rome, Italy Congress Coordinator: David H. Slangen T +39 06 88 595 250 - F +39 06 88595 234 E-mail: firstname.lastname@example.org 5 Faculty members Ahmad Awada Medical Oncology Clinic Jules Bordet Institute Brussels, Belgium Alberto Bardelli Univeristy of Torino School of Medicine Turin, Italy Fortunato Ciardiello Division of Medical Oncology Department of Experimental and Clinical Medicine and Surgery F. Magrassi and A. Lanzara Second University of Naples Naples, Italy Rolf Stahel University Hospital Zürich Zürich, Switzerland Josep Tabernero Vall d’Hebron University Hospital Vall d'Hebron Institute of Oncology (VHIO) Barcelona, Spain Eric Van Cutsem University Hospitals Gasthuisberg/Leuven Leuven, Belgium Yosef Yarden Weizmann Institute of Science Department of Biological Regulation Rehovot, Israel Christoph C. Zielinski Comprehensive Cancer Center, Vienna General Hospital and Medical University of Vienna Vienna, Austria Central European Cooperative Oncology Group (CECOG) 6 Xxxxxx Xxxxx xxxxxxxxxxx Scientific programme Scientific programme Thursday, 29 January 2015 Session I Evening session 18.00 Welcome and presentation of the Masterclass course E. Van Cutsem (Belgium) - Y. Yarden (Israel) 18.15 Opening keynote lecture: Overview on relevant molecular pathways in oncology and their pharmacological intervention Speaker to be announced 19.00 Get together dinner End of the first day 8 Friday, 30 January 2015 Session II Optional early bird session 07.30 Genome analysis methods (basics) Y. Yarden (Israel) Session III 09.00 Basics of signal transduction (terminology and specific examples) A. Bardelli (Italy) 09.30 Signal transduction pathways I: the HER family C. Zielinski (Austria) 10.00 Signal transduction pathways II: mTOR-PI3K Speaker to be announced 10.30 Signal transduction pathways III: RAS-RAF-MEK F. Ciardiello (Italy) 11.00 Coffee break 11.30 Genome analysis methods (advanced) Y. Yarden (Israel) 12.00 Biomarkers based on proteomics and high-resolution genomics/transcriptomics Speaker to be announced 12.30 Extended lunch break Poster viewing and oral poster presentations 9 Scientific programme Session IV 14.30 Controversies and panel discussion I: Cancer stem cells Moderators: Y. Yarden (Israel) - F. Ciardiello (Italy) 15.15 Controversies and panel discussion II: Tumor heterogeneity and relevance to acquired resistance to targeted therapies Moderator: J. Tabernero (Spain) 16.00 Coffee break 16.30 Essential of pharmacology of the old and new drugs A. Awada (Belgium) 17.00 The next generation of molecular targeted therapies R. Stahel (Switzerland) 17.30 End of the second day Session V Optional evening session: exercises 19.30 Science-medicine tutorials (breakthough scientific publications will be presented and discussed) Mentors: E. Van Cutsem (Belgium) Y. Yarden (Israel) 20.30 Dinner 10 Saturday, 31 January 2015 Session VI Optional early bird session 17.30 Liquid biopsy in oncology J. Tabernero (Spain) Session VII Parallel sessions 09.00 Parallel sessions Breaking news: breast cancer C. Zielinski (Austria) Breaking news: colorectal cancer E. Van Cutsem (Belgium) Breaking news: lung cancer 0 R. Stahel (Switzerland) 10.30 Coffee break 10.50 Key messages from the parallel sessions Session VIII 11.35 Design of clinical trials in the era of targeted agents: theory and practice F. Ciardiello (Italy) 12.25 Extended lunch break Poster viewing and oral poster presentations 14.25 Closing keynote lecture: Cancer immunology and immunotherapy: clinical application in melanoma Speaker to be announced 15.10 Closing remarks and end of the Masterclass course 11 Call for abstracts In the spirit of supporting the dissemination of diverse oncological research, the Steering Committee is pleased to invite the submission of abstract proposals for oral and poster presentations. Authors are requested to send their abstract via e-mail by 20 October 2014 to the following address: email@example.com Topic choices A. Signal transduction pathways in oncology B. Precision medicine in breast, colorectal and lung cancer Submission procedure Abstracts must be written in English and should not exceed 300 words. Abstract format: Title, Authors, Affiliations, Main text including background, aims, materials and methods, results and conclusions. The abstract should be structured as follows: Introduction: an informative and short background of the study Aims: outlining the main hypothesis and objectives of the study Material and Methods: indicating the number, nature and type of cohorts or material being studied, as well as the main procedures, assays, tests or treatments performed for it Results: showing the main results obtained, confirming or refuting the initial hypothesis, supported by statistics if appropriate Conclusions: stating the key learning points of the study • Abbreviations can be used after defining them first. The abstract title should reflect the contents and should be no longer than 150 characters. • List the authors with family name first, followed by initials. The name of the first author is also the presenting author. Use font size 12, Times New Roman font, and line spacing 1.5. • Authors are requested to disclose any financial support received and/or any potential conflict of interest at the end of the abstract. The Scientific Committee will review the submitted abstracts choosing the best abstracts for oral or poster presentation. The selected abstracts will be published in the abstract book to be distributed on-site to all participants. 12 Young (less than 5 years of activity in primary profession) medical oncologists whose abstract is selected for oral and poster presentations will receive a grant for their registration fee. Young medical oncologists coming from Eastern Europe (Albania, Armenia, Azerbaijan, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, the Czech Republic, Georgia, Hungary, Kosovo, Macedonia, Moldova, Montenegro, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, and Ukraine) who submit an abstract may also apply for a travel grant of € 500. EXCEMED will reward the authors of the four abstracts selected for oral presentation with a grant of € 1,000. The value of this award will be given as a voucher to be spent on participating in CME (Continuing Medical Education) courses and congresses no later than December 2015 as defined with the winner in agreement with EXCEMED. Notification of accepted abstracts will be sent by the first week of December 2014. 13 General information Venue This live educational course will take place at the: Park Inn Hotel Prague Svobodova 1 128 00 Prague, Czech Republic Tel. +420 225 995 225 Language The official language of this live educational course will be English. Registration fee The registration fee is . . . . . . . . . . . . . . . . . . . . . . . . . . . . € 500.00. The registration fee for ESMO members is . . . . . . . . . . . € 375.00. This fee includes: - Scientific sessions - Educational materials - Coffee breaks and luncheons - Dinner on 29 January - Dinner on 30 January - Certificate of attendance For any information on accommodation and registration fees please contact: David H. Slangen c/o Meridiano Congress International T +39 06 88 595 250 - F +39 06 88595 234 E-mail: firstname.lastname@example.org 14 Take a look at the oncology section of the EXCEMED website EXCEMED has made a strong commitment to medical education in oncology and is developing live events such as workshops, expert meetings and preceptorships, online activities, and other programmes that will focus on key issues in oncology and the multidisciplinary approaches to patient management. Visit the oncology section: www.oncology.excemed.org and register to access free e-learning activities and receive updates on new events and resources. All EXCEMED programmes are organized solely to promote the exchange and dissemination of scientific and medical information. No forms of promotional activities are permitted. This programme is made possible thanks to educational grants received from: Arseus Medical, Besins Healthcare, Bristol-Myers Squibb, Celgene, Centre d’Esclerosi Multiple de Catalunya (Vall d’Hebron University Hospital), Centre Hépato-Biliaire (Hôpital Paul Brousse), Croissance Conseil, CryoSave, Datanalysis, Dos33, Esaote, Ferring, Fondazione Humanitas, Fundación IVI, GE Healthcare, GlaxoSmithKline Pharmaceuticals, IPSEN, Italfarmaco, Johnson & Johnson Medical, K.I.T.E., Karl Storz, Lumenis, Merck Serono Group, PregLem, Richard Wolf Endoscopie, Sanofi-Aventis, Stallergenes, Stopler, Teva Pharma, Toshiba Medical Systems, Université Catholique de Louvain (UCL), University of Catania. Improving the patient's life through medical education www.excemed.org EXCEMED - Excellence in Medical Education Headquarters 14, Rue du Rhône - 1204 Geneva, Switzerland Representative Office Salita di San Nicola da Tolentino 1/b - 00187 Rome, Italy T +39 06 420413 1 - F +39 06 420413 677 Copyright © EXCEMED, 2014. All rights reserved.
© Copyright 2019